Cargando…

A retrospective case-cohort study comparing treatment outcomes in abacavir versus stavudine containing first line antiretroviral treatment regimens in children <3yrs old, at a paediatric programme based in Soweto, South Africa

INTRODUCTION: The current World Health Organization guideline for first line antiretroviral therapy (ART) in HIV-infected children recommends the use of abacavir and lamivudine as nucleoside backbones and no longer includes stavudine. We compared treatment outcomes with abacavir (ABC) versus stavudi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cassim, Haseena, Otwombe, Kennedy, Lazarus, Erica, Liberty, Afaaf, Gray, Glenda E., Greeff, Oppel B. W., Violari, Avy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501584/
https://www.ncbi.nlm.nih.gov/pubmed/28686654
http://dx.doi.org/10.1371/journal.pone.0180645
_version_ 1783248813227507712
author Cassim, Haseena
Otwombe, Kennedy
Lazarus, Erica
Liberty, Afaaf
Gray, Glenda E.
Greeff, Oppel B. W.
Violari, Avy
author_facet Cassim, Haseena
Otwombe, Kennedy
Lazarus, Erica
Liberty, Afaaf
Gray, Glenda E.
Greeff, Oppel B. W.
Violari, Avy
author_sort Cassim, Haseena
collection PubMed
description INTRODUCTION: The current World Health Organization guideline for first line antiretroviral therapy (ART) in HIV-infected children recommends the use of abacavir and lamivudine as nucleoside backbones and no longer includes stavudine. We compared treatment outcomes with abacavir (ABC) versus stavudine (d4T) in a cohort of HIV-1 infected children 6 and 12 months after antiretroviral therapy was initiated. METHODS: This was a retrospective case-cohort study, using programmatic data from children enrolled in the Paediatric Wellness Programme at the Perinatal HIV Research Unit in Soweto, South Africa between 2005 and 2013. Children on abacavir/stavudine who had initiated ART at age <3 years with a regimen including lamivudine and lopinavir/ritonavir and had at least one 6 or 12 month viral load result were eligible. All ABC cases identified were matched for age at ART initiation and gender to eligible d4T controls (1:2). Outcomes analysed at 6 and 12 months post ART initiation included virological failure, mortality, immunological failure and anthropometry. Chi-square tests compared categorical measures while Kruskal-Wallis compared continuous measures. RESULTS: We identified 57 eligible ABC cases and selected 114 matched d4T controls. Overall, 57% were females and 89% started treatment at age <1year. The median age at ART initiation was 3.11 (IQR: 1.98–6.05) months. There was no difference in the proportion of children virologically suppressed between the groups at 6 (ABC 54.5% vs. d4T 67.0%, p = 0.125) and 12 (ABC 66.7% vs. d4T 71.6%, p = 0.53) months post ART-initiation. The proportion of children with adherence levels >90% for ABC and d4T were similar too (95% in ABC vs. 86% in d4T, p = 0.10). The proportion of children who died over 12 months was 3.5% in the ABC and 7.9% in the d4T group (p = 0.27). Similarly, the anthropometric measures were comparable. CONCLUSIONS: It is reassuring that in the short term, in this group of patients, the treatment outcomes were similar.
format Online
Article
Text
id pubmed-5501584
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-55015842017-07-25 A retrospective case-cohort study comparing treatment outcomes in abacavir versus stavudine containing first line antiretroviral treatment regimens in children <3yrs old, at a paediatric programme based in Soweto, South Africa Cassim, Haseena Otwombe, Kennedy Lazarus, Erica Liberty, Afaaf Gray, Glenda E. Greeff, Oppel B. W. Violari, Avy PLoS One Research Article INTRODUCTION: The current World Health Organization guideline for first line antiretroviral therapy (ART) in HIV-infected children recommends the use of abacavir and lamivudine as nucleoside backbones and no longer includes stavudine. We compared treatment outcomes with abacavir (ABC) versus stavudine (d4T) in a cohort of HIV-1 infected children 6 and 12 months after antiretroviral therapy was initiated. METHODS: This was a retrospective case-cohort study, using programmatic data from children enrolled in the Paediatric Wellness Programme at the Perinatal HIV Research Unit in Soweto, South Africa between 2005 and 2013. Children on abacavir/stavudine who had initiated ART at age <3 years with a regimen including lamivudine and lopinavir/ritonavir and had at least one 6 or 12 month viral load result were eligible. All ABC cases identified were matched for age at ART initiation and gender to eligible d4T controls (1:2). Outcomes analysed at 6 and 12 months post ART initiation included virological failure, mortality, immunological failure and anthropometry. Chi-square tests compared categorical measures while Kruskal-Wallis compared continuous measures. RESULTS: We identified 57 eligible ABC cases and selected 114 matched d4T controls. Overall, 57% were females and 89% started treatment at age <1year. The median age at ART initiation was 3.11 (IQR: 1.98–6.05) months. There was no difference in the proportion of children virologically suppressed between the groups at 6 (ABC 54.5% vs. d4T 67.0%, p = 0.125) and 12 (ABC 66.7% vs. d4T 71.6%, p = 0.53) months post ART-initiation. The proportion of children with adherence levels >90% for ABC and d4T were similar too (95% in ABC vs. 86% in d4T, p = 0.10). The proportion of children who died over 12 months was 3.5% in the ABC and 7.9% in the d4T group (p = 0.27). Similarly, the anthropometric measures were comparable. CONCLUSIONS: It is reassuring that in the short term, in this group of patients, the treatment outcomes were similar. Public Library of Science 2017-07-07 /pmc/articles/PMC5501584/ /pubmed/28686654 http://dx.doi.org/10.1371/journal.pone.0180645 Text en © 2017 Cassim et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Cassim, Haseena
Otwombe, Kennedy
Lazarus, Erica
Liberty, Afaaf
Gray, Glenda E.
Greeff, Oppel B. W.
Violari, Avy
A retrospective case-cohort study comparing treatment outcomes in abacavir versus stavudine containing first line antiretroviral treatment regimens in children <3yrs old, at a paediatric programme based in Soweto, South Africa
title A retrospective case-cohort study comparing treatment outcomes in abacavir versus stavudine containing first line antiretroviral treatment regimens in children <3yrs old, at a paediatric programme based in Soweto, South Africa
title_full A retrospective case-cohort study comparing treatment outcomes in abacavir versus stavudine containing first line antiretroviral treatment regimens in children <3yrs old, at a paediatric programme based in Soweto, South Africa
title_fullStr A retrospective case-cohort study comparing treatment outcomes in abacavir versus stavudine containing first line antiretroviral treatment regimens in children <3yrs old, at a paediatric programme based in Soweto, South Africa
title_full_unstemmed A retrospective case-cohort study comparing treatment outcomes in abacavir versus stavudine containing first line antiretroviral treatment regimens in children <3yrs old, at a paediatric programme based in Soweto, South Africa
title_short A retrospective case-cohort study comparing treatment outcomes in abacavir versus stavudine containing first line antiretroviral treatment regimens in children <3yrs old, at a paediatric programme based in Soweto, South Africa
title_sort retrospective case-cohort study comparing treatment outcomes in abacavir versus stavudine containing first line antiretroviral treatment regimens in children <3yrs old, at a paediatric programme based in soweto, south africa
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501584/
https://www.ncbi.nlm.nih.gov/pubmed/28686654
http://dx.doi.org/10.1371/journal.pone.0180645
work_keys_str_mv AT cassimhaseena aretrospectivecasecohortstudycomparingtreatmentoutcomesinabacavirversusstavudinecontainingfirstlineantiretroviraltreatmentregimensinchildren3yrsoldatapaediatricprogrammebasedinsowetosouthafrica
AT otwombekennedy aretrospectivecasecohortstudycomparingtreatmentoutcomesinabacavirversusstavudinecontainingfirstlineantiretroviraltreatmentregimensinchildren3yrsoldatapaediatricprogrammebasedinsowetosouthafrica
AT lazaruserica aretrospectivecasecohortstudycomparingtreatmentoutcomesinabacavirversusstavudinecontainingfirstlineantiretroviraltreatmentregimensinchildren3yrsoldatapaediatricprogrammebasedinsowetosouthafrica
AT libertyafaaf aretrospectivecasecohortstudycomparingtreatmentoutcomesinabacavirversusstavudinecontainingfirstlineantiretroviraltreatmentregimensinchildren3yrsoldatapaediatricprogrammebasedinsowetosouthafrica
AT grayglendae aretrospectivecasecohortstudycomparingtreatmentoutcomesinabacavirversusstavudinecontainingfirstlineantiretroviraltreatmentregimensinchildren3yrsoldatapaediatricprogrammebasedinsowetosouthafrica
AT greeffoppelbw aretrospectivecasecohortstudycomparingtreatmentoutcomesinabacavirversusstavudinecontainingfirstlineantiretroviraltreatmentregimensinchildren3yrsoldatapaediatricprogrammebasedinsowetosouthafrica
AT violariavy aretrospectivecasecohortstudycomparingtreatmentoutcomesinabacavirversusstavudinecontainingfirstlineantiretroviraltreatmentregimensinchildren3yrsoldatapaediatricprogrammebasedinsowetosouthafrica
AT cassimhaseena retrospectivecasecohortstudycomparingtreatmentoutcomesinabacavirversusstavudinecontainingfirstlineantiretroviraltreatmentregimensinchildren3yrsoldatapaediatricprogrammebasedinsowetosouthafrica
AT otwombekennedy retrospectivecasecohortstudycomparingtreatmentoutcomesinabacavirversusstavudinecontainingfirstlineantiretroviraltreatmentregimensinchildren3yrsoldatapaediatricprogrammebasedinsowetosouthafrica
AT lazaruserica retrospectivecasecohortstudycomparingtreatmentoutcomesinabacavirversusstavudinecontainingfirstlineantiretroviraltreatmentregimensinchildren3yrsoldatapaediatricprogrammebasedinsowetosouthafrica
AT libertyafaaf retrospectivecasecohortstudycomparingtreatmentoutcomesinabacavirversusstavudinecontainingfirstlineantiretroviraltreatmentregimensinchildren3yrsoldatapaediatricprogrammebasedinsowetosouthafrica
AT grayglendae retrospectivecasecohortstudycomparingtreatmentoutcomesinabacavirversusstavudinecontainingfirstlineantiretroviraltreatmentregimensinchildren3yrsoldatapaediatricprogrammebasedinsowetosouthafrica
AT greeffoppelbw retrospectivecasecohortstudycomparingtreatmentoutcomesinabacavirversusstavudinecontainingfirstlineantiretroviraltreatmentregimensinchildren3yrsoldatapaediatricprogrammebasedinsowetosouthafrica
AT violariavy retrospectivecasecohortstudycomparingtreatmentoutcomesinabacavirversusstavudinecontainingfirstlineantiretroviraltreatmentregimensinchildren3yrsoldatapaediatricprogrammebasedinsowetosouthafrica